

## Original Article

# Inhibitory effects of oleoylethanolamide (OEA) on H<sub>2</sub>O<sub>2</sub>-induced human umbilical vein endothelial cell (HUVEC) injury and apolipoprotein E knockout (ApoE<sup>-/-</sup>) atherosclerotic mice

Li Ma, Xiaobing Guo, Wei Chen

Department of Cardiology, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China

Received January 23, 2015; Accepted March 22, 2015; Epub June 1, 2015; Published June 15, 2015

**Abstract:** Atherosclerosis (AS) is initiated by vascular endothelial cell injury, which is induced by lipid and protein oxidation. Oleoylethanolamide (OEA), a dietary fat-derived lipid, has shown atheroprotective effect. *In vitro* studies demonstrated that OEA showed cytoprotective effects on H<sub>2</sub>O<sub>2</sub>-induced primary cultured human umbilical vein endothelial cell (HUVEC) injury model. Further investigation of the cytoprotective effects of OEA demonstrated that OEA exerted its function by scavenging for reactive oxygen species, as well as increasing anti-oxidative enzymes, reducing lipid peroxidation, terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL)-positive cells and apoptosis-related proteins expression. The *in vivo* study using an ApoE<sup>-/-</sup> mouse model fed with high-fat diet for 8 weeks showed that OEA (10 mg/kg/day, i.g.) administration reduced blood lipid levels, prevented endothelial cell damage and inhibited early AS plaque formation. In conclusion, our results suggested that OEA exerted a pharmacological effect on ameliorating atherosclerotic plaque formation through the inhibition of oxidative stress-induced endothelial cell injury and therefore OEA can be a potential candidate drug for anti-atherosclerosis.

**Keywords:** Atherosclerosis, endothelial cell, oxidative stress, apoptosis, OEA

## Introduction

Atherosclerosis (AS) is the leading cause of coronary heart disease for its high morbidity and mortality in western developed countries [1]. Vascular endothelial cell injury is the initial event in the development of AS, which is frequently linked with endothelial dysfunction [2]. Endothelial dysfunction would trigger numbers of pathophysiologic processes, such as macrophage aggregation, vascular smooth muscle cell proliferation and ultimate atheromatous plaque formation [3, 4]. Thus, how to protect endothelial cell injury is an effective method to prevent AS.


Oxidative stress, because of a broken scale between antioxidants and pro-oxidants, is the key incentive in the development of AS [5]. The excessive reactive oxygen species (ROS) increases endothelial cell apoptosis, which is the main cause of endothelial injury [6]. The integrity of the endothelial monolayer was destroyed by endothelial cell apoptosis, leading

to the degeneration of vascular structures and increasing endothelial permeability [7]. Activation of caspase-mediated mitochondrial pathway has been notably involved in the pathogenesis of most ROS-induced endothelial cell injury [8]. Therefore, antioxidants that preferentially remove ROS may have therapeutic applications in ROS-induced endothelial injury.

Oleoylethanolamide (OEA), a natural occurring lipid and agonist of peroxisome proliferator-activated receptor alpha (PPAR- $\alpha$ ), antiobesity and has atheroprotective effects through the inhibition of low density lipoprotein (LDL) modification in vascular system [9-12]. In spite of many papers have devoted to the exploration of OEA on AS, however, the protect role of OEA on endothelial cell injury induced by oxidative stress still remain largely unknown.

In present study, we investigated the effect of OEA on H<sub>2</sub>O<sub>2</sub>-induced HUVEC injury and atherosclerosis development in high fat diet (HFD)-induced ApoE<sup>-/-</sup> atherosclerosis mice. Our data

## Cardiology of oleoylethanolamide



**Figure 1.** OEA protects against H<sub>2</sub>O<sub>2</sub>-induced cytotoxicity in HUVEC. A. The HUVECs were treated for 6, 12, 24, 48 h with different concentrations of H<sub>2</sub>O<sub>2</sub>. Cell viability was determined by CCK-8 assay expressed as percent relative to untreated control. B. HUVECs were pretreated with OEA (25, 50, and 100 μg/ml) for 8 h and then incubated with or without H<sub>2</sub>O<sub>2</sub> (100 μM) for 24 h, and cell viability was assayed. C. HUVECs were incubated with OEA alone (25, 50, and 100 μM) for 8 h and cell viability was assayed. Values (n = 3 per group) are expressed as means ± S.E. \*P < 0.05, \*\*P < 0.01 compared with control group; #P < 0.05, ##P < 0.01 compared with H<sub>2</sub>O<sub>2</sub>-treated group.

showed that OEA could prevent H<sub>2</sub>O<sub>2</sub>-induced HUVEC injury and ameliorate atherosclerotic plaque formation. Thus, OEA may be a potential candidate for anti-atherosclerosis drug.

### Materials and methods

#### Reagents

Oleoylethanolamide (≥ 98%), H<sub>2</sub>O<sub>2</sub>, dimethylsulfoxide (DMSO), oil red O were obtained from Sigma-Aldrich (St. Louis, MO, USA). The cell counting kit-8 was obtained from Dojindo laboratory (Japan). M-200 medium and low-serum growth supplements were obtained from Invitrogen Corporation (New York, NY, USA). The kits for determining superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-px) activity were purchased from Jiancheng Bioengineering Institute (Nanjing, China). Triacylglycerol (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) commercial kits were purchased from Zhongsheng Bio-tech Co., Ltd. (Beijing, China). The enzyme-linked immunosorbent assay (ELISA) kits of human 4-hydroxynonenal (HNE), mouse-soluble intercellular adhesion molecule-1 (sICAM-1), mouse-monocyte chemoattractant protein 1 (MCP-1), mouse C-reactive protein (CRP) were obtained from R&D Systems Inc. (Minneapolis, MN, USA). The terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay kit was purchased from Roche Diagnostics GmbH (Mannheim, Germany). Caspase-3 activity and ROS fluorometric assay kits were purchased from Biovision Inc. (Palo Alto, CA, USA). All primary and sec-

ondary antibodies labeled with horseradish peroxidase-conjugated goat anti-mouse and goat-anti rabbit IgG were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA).

#### Cell culture and treatment

Human umbilical vein endothelial cells (HUVEC) were isolated from fresh human umbilical veins using 0.1% collagenase I. The neonate cords were donated by the Maternal and Child Care Service Centre in our hospital. The M-200 medium with low-serum growth supplements, penicillin (100 U/ml), and streptomycin (100 μg/ml) were used for the HUVEC culture. The HUVECs were treated with OEA (100 μM) for 8 h before testing for the presence of 100 μM H<sub>2</sub>O<sub>2</sub> (24 h).


#### Cell proliferation assay

Cell viability analyzed by a Cell Counting Kit-8 (CCK-8) (Dojindo Molecular Technologies, Shanghai, China). The HUVECs were incubated on 96-well plates at a density of 8,000 cells per well and cultured for 24 hours. Cell media were removed; the cells were incubated with tetrazolium reagent for 1 hour and then washed with PBS. Colorimetric dye was tested at wavelength 450 nm in spectrophotometer. The data were obtained from three independent experiments.

#### Measurement of CAT, 4-HNE and GSH-px levels and SOD activity

The HUVEC cells were cultured in six-well plates at 3 × 10<sup>5</sup> cells/well. The supernatant and cells were collected respectively after the indicated

## Cardiology of oleoylethanolamide



**Figure 2.** OEA decreases intracellular ROS level and caspase-3 activation. A. The HUVECs were treated for 6, 12, 24, 48 h with different concentrations of H<sub>2</sub>O<sub>2</sub>. Cell viability was determined by CCK-8 assay expressed as percent relative to untreated control. B. HUVECs were pretreated with OEA (25, 50, and 100 μg/ml) for 8 h and then incubated with or without H<sub>2</sub>O<sub>2</sub> (100 μM) for 24 h, and cell viability was assayed. C. HUVECs were incubated with OEA alone (25, 50, and 100 μM) for 8 h and cell viability was assayed. Values (n = 3 per group) are expressed as means ± S.E. #P < 0.05, ##P < 0.01 compared with control group; □P < 0.05, □□P < 0.01 compared with H<sub>2</sub>O<sub>2</sub>-treated group.

treatments for detecting CAT, 4-HNE and MDA levels as well as SOD activity using the corresponding detection kits according to the manufacturer's brochures.

### Detection of intracellular ROS production

The effect of OEA on intracellular ROS levels was tested using the total ROS detection kit according to the manufacturer's instructions (Enzo Life Sciences Inc., Farmingdale, NY, USA) as previously described [13]. Briefly, following drug treatment, the HUVEC cells were harvested and washed with 1 × washing buffer, and then the cells were incubated with 100 μl of 5-(and-6)-carboxy-2, 7-dichlorodihydrofluorescein diacetate (carboxy-H<sub>2</sub>DCFDA) (25 μM final concentration) in darkness at 37°C for 30 min. Cellular DCF fluorescence intensity was determined through microplate reader with excitation wavelength of 495 nm and emission wavelength of 529 nm. The ROS level was expressed as a percentage of the control.

### TUNEL assay

The DNA fragmentation was tested by the TUNEL kit. Briefly, HUVEC cells were cultured on cover slips overnight. After exposure to 100 μM H<sub>2</sub>O<sub>2</sub> for 24 h, cells were fixed by incubation in 4% neutral buffered formalin solution for 30 min at room temperature. HUVECs were incubated with a 0.3% H<sub>2</sub>O<sub>2</sub> methanol solution for 15 min at room temperature to inactivate endogenous peroxidase activity. Then, cells were treated with a permeabilizing solution (0.1% sodium citrate and 0.1% Triton X-100) at

4°C for 1 min. Subsequently, cells were incubated in the TUNEL reaction mixture at 37°C for 60 min and visualized by fluorescence microscopy (DM4000B, Leica, Wetzlar, Germany). The apoptotic cells were counted in at least 100 cells from five randomly selected fields in each sample, and counts were expressed as a percentage of the total number of cells.


### Analysis of caspase-3 activation

Caspase-3 activation was detected using a fluorescein active caspase-3 staining kit (BioVision). HUVECs (1 × 10<sup>6</sup> cells/mL) were re-suspended in 50 μL of chilled lysis buffer and incubated on ice for 10 min. Approximately 50 μL of 2 × reaction buffer (containing 10 mM dithiothreitol, DTT) and 5 μL of 1 mM DEVD-AFC substrate was added to each sample, which was then incubated at 37°C for 2 h. Fluorescence was tested on a microplate reader (Spectrafluor, TECAN, Sunrise, Austria) with an excitation wavelength of 400 nm and an emission wavelength of 505 nm.

### Western blot

Protein levels of Bax, Bcl-2, caspase-3 were determined in the HUVECs. Cytoplasmic extracts were obtained by lysing the cells in lysis buffer containing 1% protease inhibitors. The cell lysates were centrifuged at 13,000 rpm for 15 min at 4°C, and the supernatant was obtained. Protein content was detected using a bicinchoninic acid assay. Equal amounts of the protein (30 μg) were separated on 10% sodium dodecyl sulfate polyacrylamide gel and

Cardiology of oleoylethanolamide



**Figure 3.** OEA treatment reverses H<sub>2</sub>O<sub>2</sub>-induced lipid peroxidation and cellular antioxidant potential descent and inhibits H<sub>2</sub>O<sub>2</sub>-induced HUVEC apoptosis. A. Effects of OEA on the production of SOD, GSH-px, CAT, 4-HNE activity. B. Effect of OEA on H<sub>2</sub>O<sub>2</sub>-induced HUVEC apoptosis by TUNEL staining. C. Statistic data of TUNEL-positive cells. D. Apoptosis related proteins expression detected by western blot. E. Statistic data of Bax, Bcl-2, caspase-3 expression compared with control group. Values (n = 3 per group) are expressed as means ± S.E. ##P < 0.01 compared with control group; □P < 0.05, □□P < 0.01 compared with H<sub>2</sub>O<sub>2</sub>-treated group.

transferred onto nitrocellulose membranes. These membranes were blocked with 3% bovine serum albumin in Tris-buffered saline containing 0.1% Tween-20 (TBST) for 2 h at room temperature. The membranes were incubated overnight with primary antibodies at 4°C, washed with TBST, incubated with HRP-conjugated IgG at room temperature for 1 h, washed in TBST, and the membranes were visualized by enhanced chemiluminescence. Band intensity was measured and quantified.

### Animals

Male C57BL/6N and ApoE<sup>-/-</sup> mice (6 weeks old) were provided by the Experimental Animal Center of Medical Department of Peking University. All animal care procedures were executed in accordance with the Guidelines and Policies for Animal Surgery provided by our institute (Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China) and were permitted by the Institutional Animal Use and Care Committee as previously reported [14]. The mice were maintained in a temperature-controlled facility (temperature: 22°C ± 1°C, humidity: 60%) with a 14 h light/10 h dark photoperiod and free access to food and water. Ten male C57BL/6N mice comprised the control group (n = 10). Twenty male ApoE<sup>-/-</sup> mice were divided randomly into a model group (n = 10), OEA group (n = 10). All mice were fed a high fat diet (containing 0.3% cholesterol and 20% fat) for 8 weeks. The animals in the OEA group were orally administered OEA (10 mg/kg/day, i.g.) constantly for 8 weeks, whereas the other groups were given the same volume of vehicle. The mice were fasted for 4 h at the start and end period of the experiment and blood samples were collected from their inner canthus for serum preparation. The serum was stored at -80°C prior to analysis. At the end of the administration, all mice were euthanized by cervical dislocation, and the hearts and proximal aortae were removed and fixed in 4% formalin. The hearts were then cut directly under and parallel to the aortic cusps. The upper portions were embedded in an optimum cutting

temperature (OCT) compound and frozen at -80°C. The samples were cut into 50 cross-sections and were used in the subsequent analyses.

### Levels of lipids and inflammatory factors in the serum of mice

At the end of the experiment, the serum LDL-C, TC, TG and HDL-C were detected by a Hitachi 7600 Automatic Biochemistry Analyzer (Tokyo, Japan) and serum inflammatory factors CRP, sICAM-1, MCP-1 were measured by ELISA assays according to the brochures.


### Oil red O staining

The atherosclerotic plaque area in each aortic section was assessed under oil red O staining using Image-Pro Plus (Media Cybernetics Inc., Silver Spring, MD). Briefly, hearts were embedded in Tissue-Tek OCT compound at -20°C, and sections were obtained through the aorta root. Subsequently, frozen sections were immersed in 60% isopropanol and stained in oil red O for 55 min at 60°C. Then, the sections were washed by deionized water and cell nucleus was stained by hematoxylin. To evaluate the seriousness of the lesions, the ratio of the oil red O-positive area was compared with the whole vessel area, including the lumen, intima, media, and adventitia, as previously described [15]. Every five section from each animal was examined, and the mean fraction area was calculated and expressed as a percentage.

### Assessment of EC apoptosis in mice aortae

DNA fragmentation in the ECs was measured using the TUNEL staining kit according to the manufacturer's instructions. Frozen sections of the aortae from the ApoE<sup>-/-</sup> mice were maintained for 15 min at room temperature and washed with PBS to remove the OCT compound. The TUNEL reaction mixture was added to the sections, which were subsequently incubated for 1 h at 37°C in darkness. After incubation, the cells were washed twice for 5 min in PBS

## Cardiology of oleoylethanolamide



**Figure 4.** OEA reduces the atherosclerotic plaque in the aorta of ApoE<sup>-/-</sup> mice. A. Levels of CRP, MCP-1, sICAM-1 expression measured by ELISA in mice at 8 weeks of the administration. B. Atherosclerotic lesion formation under Oil Red O staining in mice at 8 weeks of the administration. C. Statistical data of lipid accumulation in the aortic root. D. Blood lipid levels of serum in mice at 8 weeks of the administration. Values (n = 10 per group) are expressed as means ± S.E. **##**P < 0.01 compared with C57 control group; **□**P < 0.05, **□□**P < 0.01, compared with vehicle treated ApoE<sup>-/-</sup> model group.

and stained with DAPI solution. After rinsing twice for 5 min in PBS, the samples were observed under a fluorescence microscope (Leica DM4000, Germany). The ratio of TUNEL-positive cells was calculated according to the previous method [14].

### *Immunofluorescence*

Endothelial cell caspase-3 deposition in the aortic arch was measured through immunofluorescence. Briefly, the aorta sections from the ApoE<sup>-/-</sup> mice were incubated overnight at 4°C with anti-caspase-3 rabbit polyclonal antibodies (1:100). After rinsing, the sections were incubated with anti-rabbit FITC anti bodies (1:100) for 45 min at room temperature and then incubated with DAPI for 5 min. Then the sections were mounted with the fluorescence quenching agent and the samples were observed under a fluorescence microscope (Leica DM4000, Germany). Caspase-3 expression was quantified using Image-Pro Plus 6.0.

### *Statistical analysis*

Results are expressed as mean  $\pm$  S.E. Differences between the groups were analyzed using one-way ANOVA, followed by a t test. Differences with  $P < 0.05$  were considered statistically significant.

## **Results**

### *OEA protects against H<sub>2</sub>O<sub>2</sub>-induced cytotoxicity in HUVEC*

Firstly, in order to obtain the optimized oxidative stress conditions, we investigate HUVECs treated for 6, 12, 24, and 48 h with different H<sub>2</sub>O<sub>2</sub> concentrations. Cell viabilities were tested using CCK-8 assay. As shown in **Figure 1A**, a dose and time-dependent increase of cytotoxicity on HUVECs were observed in response to H<sub>2</sub>O<sub>2</sub>. Cell viability was reduced to 50.2%  $\pm$  2.5% at 100  $\mu$ M H<sub>2</sub>O<sub>2</sub> treated for 24 h, which was the concentration selected for the next experiments. To assess the cytoprotective effect of OEA, HUVECs were pretreated with different concentrations (25, 50, 100  $\mu$ M) of OEA for 8 h, followed by 24 h of 100  $\mu$ M H<sub>2</sub>O<sub>2</sub> treatment. As shown in **Figure 1B**, to our excitement, OEA pretreatment groups showed a significant increase in cell viability, the cell viability from 49.9%  $\pm$  2.2% up to 70.9%  $\pm$  7.3% at 100  $\mu$ M,

which indicates that OEA pretreatment protects against H<sub>2</sub>O<sub>2</sub>-induced cell damage. To exclude the proliferative and toxic effects of OEA, we also evaluated the OEA treatment alone on the cell viability level. As shown in **Figure 1C**, treatment with OEA 8 h did not significantly influence cell proliferation and survival, therefore, OEA treatment alone does not significantly influence cell viability.

### *OEA decreases intracellular ROS level and caspase-3 activation*


Oxidative stress may lead to the up-regulation of ROS in cardiovascular diseases [3]. As **Figure 4** shown, OEA pretreatment can significantly decrease ROS level compared with H<sub>2</sub>O<sub>2</sub> treated group. The activation of the caspase-3 is crucial in the initiation of apoptosis in diverse biological processes. Our results show that 100  $\mu$ M H<sub>2</sub>O<sub>2</sub> significantly increased the caspase-3 activity, whereas the addition of OEA to the culture system significantly suppressed H<sub>2</sub>O<sub>2</sub>-induced caspase-3 activation in **Figure 4**.

### *OEA treatment reverses H<sub>2</sub>O<sub>2</sub>-induced lipid peroxidation and cellular antioxidant potential descent*

One of the primary events in oxidative damage is the membrane lipid oxidation, which can be determined by its degradation products 4-HNE [16]. As shown in **Figure 2A**, treatment with 100  $\mu$ M H<sub>2</sub>O<sub>2</sub> notably increased the intracellular 4-HNE levels, whereas significantly decreased the antioxidant enzymes CAT, SOD, and GSH-Px activity. However, pretreatment with different concentrations of OEA markedly decreased the 4-HNE levels and increased the antioxidant enzymes activity. These results were coincident with the serum level of inflammatory factors, CRP, MCP-1, sICAM-1 *in vivo* as shown in **Figure 3A**. The aforementioned results showed that OEA can increase the antioxidative ability of the damaged endothelial cells.

### *OEA inhibits H<sub>2</sub>O<sub>2</sub>-induced HUVEC apoptosis*

Apoptosis in HUVEC was detected using TUNEL staining. As shown in **Figure 2B** and **2C**, treatment with 100  $\mu$ M H<sub>2</sub>O<sub>2</sub> for 24 h obviously increased the number of apoptotic cells. However, pretreatment with 100  $\mu$ M OEA for 8 h reduced the TUNEL-positive cells. Next, we



**Figure 5.** OEA protects against endothelial damage in the aorta of ApoE<sup>-/-</sup> mice. A. Endothelial cell apoptosis under TUNEL staining. B. Caspase-3 expression on immunofluorescence staining. C. Statistical data of TUNEL-positive cells. D. Statistical data of caspase-3 cells. Values (n = 10 per group) are expressed as means ± S.E. <sup>##</sup>P < 0.01 compared with C57 control group; \*P < 0.05, <sup>\*\*</sup>P < 0.01, compared with vehicle treated ApoE<sup>-/-</sup> model group.

investigated the effects of OEA on apoptosis-related proteins expression. As shown in **Figure 2**, H<sub>2</sub>O<sub>2</sub> significantly increased the pro-apoptosis proteins Bax and caspase-3 expression as well as decreased the anti-apoptosis protein Bcl-2 expression. However, treatment with OEA significantly reversed the H<sub>2</sub>O<sub>2</sub> injury.

*OEA reduces the atherosclerotic plaque in the aorta of ApoE<sup>-/-</sup> mice*

To assess the cytoprotective function of OEA in vivo, we established an experimental ApoE<sup>-/-</sup> AS mice model following the method previously described [14, 15]. After 8 weeks of OEA (10



mg/kg) administration, we initially measured the effect of OEA on serum lipids LDL-C, HDL-C, TC and TG levels. As shown in **Figure 3D**, the serum lipid levels in ApoE<sup>-/-</sup> model group were remarkably higher than those in C57BL/6N control group and OEA administration group could reduce the lipid levels. We also evaluated the AS plaque formation in the experimental ApoE<sup>-/-</sup> mice. As shown in **Figure 3B** and **3C**, OEA (10 mg/kg) remarkably reduced the oil red O positive plaque area in the experimental ApoE<sup>-/-</sup> mice compared with the C57 group. These results showed that OEA treatment may inhibit atherosclerotic plaque formation in the aorta of ApoE<sup>-/-</sup> mice.

### *OEA protects against endothelial damage in the aorta of ApoE<sup>-/-</sup> mice*

(**Figure 5**) Excessive ROS levels causing oxidative injury play a crucial role in the pathogenesis of AS [17]. To assess the cytoprotective function of OEA *in vivo*, we established an experimental AS mice model as the method described previously [18]. As shown in **Figure 4A** and **4C**, the ratio of apoptotic EC in the aortic arch vessel was significantly decreased in the OEA treatment group compared with the model group. We also evaluated caspase-3 activation. As shown in **Figure 4B** and **4D**, OEA treatment remarkably decreased the activated caspase-3 expression compared with the ApoE<sup>-/-</sup> model mice. These results suggest that OEA treatment *in vivo* inhibits AS development.

### Discussion

Endothelial dysfunction and cellular injury that caused by oxidative stress play crucial roles in the development of AS [19]. In the normal conditions, ROS levels in the plasma are maintained in low levels by reacting with heme proteins [20]. However, under pathologic conditions, such as hypertension, hyperlipidemia, obesity, and diabetes could cause an increase of ROS levels [21]. Also, the increased ROS levels may induce endothelial cell apoptosis from oxidative stress [22]. Therefore, protecting endothelial cells from ROS-induced damage is an effective treatment for the AS.

OEA, a naturally occurring lipid, has many pharmacological activities, anti-obesity [12, 23], neuroprotection [24], and anti-atherosclerosis

[25]. Fan and his colleagues referred that OEA played a key role in AD lesion development via targeting oxidized LDL [9]. In this study, we investigated the effects of OEA on H<sub>2</sub>O<sub>2</sub>-induced endothelial cell injury *in vitro* and high-fat diet-induced ApoE<sup>-/-</sup> AS mice *in vivo*. After exposed to H<sub>2</sub>O<sub>2</sub>, HUVEC exhibited high oxidative stress injury, such as increased ROS level, caspase-3 activation, up-regulation of oxidative enzymes and down-regulation of anti-oxidative enzymes. Furthermore, H<sub>2</sub>O<sub>2</sub> group showed a more TUNEL-positive cells. However, pretreatment with OEA may reverse the H<sub>2</sub>O<sub>2</sub>-induced aforementioned effects. AS is considered as a chronic inflammatory disease and inflammation is also characterized by excessive ROS production [26]. So, these results suggested that the protective effect of OEA against oxidative stress induced endothelial cell injury may be due to its ability to inhibit ROS production. Excessive ROS may cause cell apoptosis. So, we also evaluated the effects of OEA on apoptosis-related proteins expression in H<sub>2</sub>O<sub>2</sub>-induced HUVEC damage. In accordance with the result of cytoprotective effects, OEA treatment can increase the anti-apoptosis protein Bcl-2 expression, whereas decrease the pro-apoptosis proteins expression, such as Bax and caspase-3. We also confirmed the protective effects of OEA against endothelial cell damage *in vivo*. OEA administration can significantly decrease endothelial cell caspase-3 activation and apoptosis in the aorta of ApoE<sup>-/-</sup> mice.

Previous studies revealed that the increasing of blood lipid levels is the characteristic of AS [27, 28]. Lopez and his colleagues have demonstrated that blood lipid levels was associated with atrial fibrillation, which was a risk factor for AS [29]. In this study, to assess the effect of OEA on HFD-induced ApoE<sup>-/-</sup> AS mice, we measured the lipid accumulation in the aortic root by oil red O. Our results showed that the blood lipid level of mice in OEA treatment group could be remarkably decreased by OEA compared with that in the model group, indicating that OEA may performed an important inhibition role on AS. Meanwhile, the cytokines level in the plasma were also measured, our results displayed that OEA administration group could decrease the MCP-1, CRP, sICAM-1 levels, which was consistent with the *in vitro* experiment.

In conclusion, our study attempts to investigate the potential role of OEA on H<sub>2</sub>O<sub>2</sub>-induced HUVEC injury and apolipoprotein E knockout (ApoE<sup>-/-</sup>) AS mice. OEA may play an important role in protecting HUVECs against H<sub>2</sub>O<sub>2</sub>-induced apoptosis and ameliorates AS plaque formation. The underlying mechanism is related to its antioxidant activity. AS, a chronic inflammatory procession, is initiated by EC dysfunction [30]. Our study may provide evidence that OEA treatment may be a potential drug for treating AS. However, further experimental studies are still needed to explore the molecular mechanism of OEA on protecting AS induced by oxidase stress.

### Disclosure of conflict of interest

None.

**Address correspondence to:** Dr. Li Ma, Department of Cardiology, Beijing Tiantan Hospital, Capital Medical University, 6 Tiantan Xili Road, Dongcheng District, Beijing 100050, PR China. E-mail: lima66@126.com

### References

- [1] Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D and Turner MB. Executive summary: heart disease and stroke statistics—2014 update: a report from the American Heart Association. *Circulation* 2014; 129: 399-410.
- [2] Ross R and Kariya B. Morphogenesis of vascular smooth muscle in atherosclerosis and cell culture. *Comprehensive Physiology* 2011.
- [3] Griendling KK and FitzGerald GA. Oxidative stress and cardiovascular injury: Part I: basic mechanisms and in vivo monitoring of ROS. *Circulation* 2003; 108: 1912-1916.
- [4] Griendling KK and FitzGerald GA. Oxidative stress and cardiovascular injury: Part II: animal and human studies. *Circulation* 2003; 108: 2034-2040.
- [5] Li H, Horke S and Förstermann U. Vascular oxidative stress, nitric oxide and atherosclerosis. *Atherosclerosis* 2014; 237: 208-219.
- [6] Ray R and Shah AM. NADPH oxidase and endothelial cell function. *Clin Sci (Lond)* 2005; 109: 217-226.
- [7] Dimmeler S and Zeiher AM. Endothelial cell apoptosis in angiogenesis and vessel regression. *Circulation research* 2000; 87: 434-439.
- [8] Boatright KM and Salvesen GS. Mechanisms of caspase activation. *Curr Opin Cell Biol* 2003; 15: 725-731.
- [9] Fan A, Wu X, Wu H, Li L, Huang R, Zhu Y, Qiu Y, Fu J, Ren J and Zhu C. Atheroprotective Effect of Oleoylethanolamide (OEA) Targeting Oxidized LDL. *PLoS One* 2014; 9: e85337.
- [10] Fu J, Astarita G, Gaetani S, Kim J, Cravatt BF, Mackie K and Piomelli D. Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine. *J Biol Chem* 2007; 282: 1518-1528.
- [11] Fu J, Gaetani S, Oveisi F, Lo Verme J, Serrano A, Rodriguez De Fonseca F, Rosengarth A, Luecke H, Di Giacomo B, Tarzia G and Piomelli D. Oleoylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. *Nature* 2003; 425: 90-93.
- [12] Grosshans M, Schwarz E, Bumb JM, Schaefer C, Rohleder C, Vollmert C, Vollstadt-Klein S, Tost H, Meyer-Lindenberg A, Kiefer F and Leweke FM. Oleoylethanolamide and human neural responses to food stimuli in obesity. *JAMA Psychiatry* 2014; 71: 1254-61.
- [13] Wang M, Sun GB, Sun X, Wang HW, Meng XB, Qin M, Sun J, Luo Y and Sun XB. Cardioprotective effect of salvianolic acid B against arsenic trioxide-induced injury in cardiac H9c2 cells via the PI3K/Akt signal pathway. *Toxicol Lett* 2013; 216: 100-107.
- [14] Sun GB, Qin M, Ye JX, Pan RL, Meng XB, Wang M, Luo Y, Li ZY, Wang HW and Sun XB. Inhibitory effects of myricitrin on oxidative stress-induced endothelial damage and early atherosclerosis in ApoE<sup>-/-</sup> mice. *Toxicol Appl Pharmacol* 2013; 271: 114-126.
- [15] Harauma A, Murayama T, Ikeyama K, Sano H, Arai H, Takano R, Kita T, Hara S, Kamei K and Yokode M. Mulberry leaf powder prevents atherosclerosis in apolipoprotein E-deficient mice. *Biochem Biophys Res Commun* 2007; 358: 751-756.
- [16] Katayama Y, Inaba T, Nito C, Ueda M and Katsura K. Neuroprotective effects of erythromycin on cerebral ischemia reperfusion-injury and cell viability after oxygen-glucose deprivation in cultured neuronal cells. *Brain Res* 2014; 1588: 159-67.
- [17] Harrison CM, Pompilius M, Pinkerton KE and Ballinger SW. Mitochondrial oxidative stress significantly influences atherogenic risk and cytokine-induced oxidant production. *Environ Health Perspect* 2011; 119: 676-681.

- [18] Nakashima Y, Plump AS, Raines EW, Breslow JL and Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. *Arterioscler Thromb* 1994; 14: 133-140.
- [19] Xi H, Akishita M, Nagai K, Yu W, Hasegawa H, Eto M, Kozaki K and Toba K. Potent free radical scavenger, edaravone, suppresses oxidative stress-induced endothelial damage and early atherosclerosis. *Atherosclerosis* 2007; 191: 281-289.
- [20] Halliwell B, Clement MV and Long LH. Hydrogen peroxide in the human body. *FEBS Lett* 2000; 486: 10-13.
- [21] Dali-Youcef N, Mecili M, Ricci R and Andres E. Metabolic inflammation: connecting obesity and insulin resistance. *Ann Med* 2013; 45: 242-253.
- [22] Urbanski K, Nowak M and Guzik TJ. [Oxidative stress and vascular function]. *Postepy Biochem* 2013; 59: 424-431.
- [23] Romano A, Coccarello R, Giacobozzo G, Bedse G, Moles A and Gaetani S. Oleoylethanolamide: a novel potential pharmacological alternative to cannabinoid antagonists for the control of appetite. *Biomed Res Int* 2014; 2014: 203425.
- [24] Gonzalez-Aparicio R, Blanco E, Serrano A, Pavon FJ, Parsons LH, Maldonado R, Robledo P, Fernandez-Espejo E and de Fonseca FR. The systemic administration of oleoylethanolamide exerts neuroprotection of the nigrostriatal system in experimental Parkinsonism. *Int J Neuropsychopharmacol* 2014; 17: 455-468.
- [25] Montecucco F, Matias I, Lenglet S, Petrosino S, Burger F, Pelli G, Braunersreuther V, Mach F, Steffens S and Di Marzo V. Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. *Atherosclerosis* 2009; 205: 433-441.
- [26] Jo H, Song H and Mowbray A. Role of NADPH oxidases in disturbed flow- and BMP4- induced inflammation and atherosclerosis. *Antioxid Redox Signal* 2006; 8: 1609-1619.
- [27] Franczyk-Zarow M, Kostogryb RB, Szymczyk B, Jawien J, Gajda M, Cichocki T, Wojnar L, Chlopicki S and Pisulewski PM. Functional effects of eggs, naturally enriched with conjugated linoleic acid, on the blood lipid profile, development of atherosclerosis and composition of atherosclerotic plaque in apolipoprotein E and low-density lipoprotein receptor double-knockout mice (apoE/LDLR<sup>-/-</sup>). *Br J Nutr* 2008; 99: 49-58.
- [28] Veniant MM, Beigneux AP, Bensadoun A, Fong LG and Young SG. Lipoprotein size and susceptibility to atherosclerosis—insights from genetically modified mouse models. *Curr Drug Targets* 2008; 9: 174-189.
- [29] Lopez FL, Agarwal SK, MacLehose RF, Soliman EZ, Sharrett AR, Huxley RR, Konety S, Ballantyne CM and Alonso A. Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation: the atherosclerosis risk in communities study. *Circ Arrhythm Electrophysiol* 2012; 5: 155-162.
- [30] Kriszbacher I, Koppan M and Bodis J. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med* 2005; 353: 429-430.